TY - JOUR
T1 - Association between renal function and chemotherapy-related toxicity in older adults with cancer
AU - Peterson, Lindsay L.
AU - Hurria, Arti
AU - Feng, Tao
AU - Mohile, Supriya G.
AU - Owusu, Cynthia
AU - Klepin, Heidi D.
AU - Gross, Cary P.
AU - Lichtman, Stuart M.
AU - Gajra, Ajeet
AU - Glezerman, Ilya
AU - Katheria, Vani
AU - Zavala, Laura
AU - Smith, David D.
AU - Sun, Can Lan
AU - Tew, William P.
N1 - Funding Information:
This work was supported by the National Institutes of Health [K23 Ag026749-01 to A.H.] and Paul Beeson Career Development Award In Aging Research [K23 Ag026749-01 to A.H.].
Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Purpose To evaluate the association between renal function (RF) and chemotherapy-related toxicity (CRT) in older adults with cancer and to compare the effect of different RF formulas and body weight measurements on this association. Methods This is a secondary analysis of data from a prospective multicenter study of patients ≥ age 65 who were starting a new chemotherapy regimen. RF was estimated with 4 formulas (modified Jelliffe [Jelliffe], Cockcroft–Gault [CG], Wright, and Modification of Diet in Renal Disease [MDRD]), using actual, ideal and adjusted body weights for 492 patients. The association between baseline RF and grade 3–5 CRT was evaluated by unconditional logistic regression. Results As a continuous variable, decreased creatinine clearance (CrCl) calculated by CG with actual body weight was associated with increased odds of CRT (OR 1.12, P < 0.01; 95% CI 1.04–1.20) indicating that on average for every 10 mL/min decrease in CrCl the odds of CRT increased by 12%. Very low RF (in the lowest 10%) with all formulas (CG, Jelliffe, Wright and MDRD) was associated with increased odds for CRT. This association is independent of the type of chemotherapy received (those requiring dose adjustment for renal function vs not). Neither primary dose reduction nor chemotherapy duration was associated with CRT. Serum creatinine alone was not associated with increased odds of CRT (OR 0.67, P = 0.15). Conclusions Decreased RF is associated with increased odds of CRT and should be considered when assessing risk of CRT in older adults with cancer. Serum creatinine alone is not adequate for risk assessment.
AB - Purpose To evaluate the association between renal function (RF) and chemotherapy-related toxicity (CRT) in older adults with cancer and to compare the effect of different RF formulas and body weight measurements on this association. Methods This is a secondary analysis of data from a prospective multicenter study of patients ≥ age 65 who were starting a new chemotherapy regimen. RF was estimated with 4 formulas (modified Jelliffe [Jelliffe], Cockcroft–Gault [CG], Wright, and Modification of Diet in Renal Disease [MDRD]), using actual, ideal and adjusted body weights for 492 patients. The association between baseline RF and grade 3–5 CRT was evaluated by unconditional logistic regression. Results As a continuous variable, decreased creatinine clearance (CrCl) calculated by CG with actual body weight was associated with increased odds of CRT (OR 1.12, P < 0.01; 95% CI 1.04–1.20) indicating that on average for every 10 mL/min decrease in CrCl the odds of CRT increased by 12%. Very low RF (in the lowest 10%) with all formulas (CG, Jelliffe, Wright and MDRD) was associated with increased odds for CRT. This association is independent of the type of chemotherapy received (those requiring dose adjustment for renal function vs not). Neither primary dose reduction nor chemotherapy duration was associated with CRT. Serum creatinine alone was not associated with increased odds of CRT (OR 0.67, P = 0.15). Conclusions Decreased RF is associated with increased odds of CRT and should be considered when assessing risk of CRT in older adults with cancer. Serum creatinine alone is not adequate for risk assessment.
KW - Chemotherapy toxicity
KW - Creatinine clearance
KW - Older adults
KW - Renal function
UR - http://www.scopus.com/inward/record.url?scp=85006817960&partnerID=8YFLogxK
U2 - 10.1016/j.jgo.2016.10.004
DO - 10.1016/j.jgo.2016.10.004
M3 - Article
C2 - 27856262
AN - SCOPUS:85006817960
SN - 1879-4068
VL - 8
SP - 96
EP - 101
JO - Journal of Geriatric Oncology
JF - Journal of Geriatric Oncology
IS - 2
ER -